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 Reporting medication errors 
and near misses 
 Sheena   Williamson 
 Medication safety incidents 
 Introduction 
 Between January 2005 and June 2006 there were 59 802 medication safety incidents 
reported via the National Reporting and Learning System (NRLS) in England and 
Wales. Medication incidents are the second most commonly reported incident next to 
patient accidents (NPSA,  2007 ). 
 Although there has been an increase in reporting over the last 3 years, literature 
suggests gross inconsistencies and substantial under-reporting from a large number 
of NHS organizations (NPSA,  2007 ). Th is has been borne out in a systematic review 
of international literature from 12 countries suggesting the average rate of under-
reporting of adverse drug events as high as 94% (Hazell & Shakir,  2006 ). 
 A signifi cant proportion of low reporting or non-reporting has arisen from pri-
mary care organizations with only 4.9% of the total medication incidents reported to 
the NRLS coming from the primary care  setting. 
 Th e aim of this chapter is to defi ne what is meant by medication safety incidents and 
to examine where errors are likely to occur within the medication process, including a 
brief overview of some of the fi ndings in the data that are pertinent to reporting medica-
tion incidents from the National Patient Safety Agency Report ( 2007 ) Safety in doses: 
medication safety incidents in the NHS. Th e main section in the chapter consists of 
guidance on how to report medication incidents, utilizing the recommendations from 
NPSA on how to improve  reporting. 
 Terms and defi nitions 
 Th e National Patient Safety Agency (NPSA) has defi ned a patient safety incident as 
‘any unintended or unexpected incident which could have or did lead to harm for one 
or more patients’ (NPSA,  2004 ). A wide variety of terms are used in the defi nition and 
classifi cation of medication safety incidents and it is important to understand the dif-
ferences between each of these. Th e model in  Fig. 10. 1 demonstrates the correlation 
between the terms explained below. 
 Medication errors are broadly defi ned as incidents in which an error has occurred some-
where in the medication process, regardless of whether any harm occurred to the patient. 
 Potential Adverse Drug Events (near misses) may be identifi ed as incidents which 
did not cause any harm at the time but may have had the potential to cause harm. Near 
misses are oft en under reported and yet they provide rich data to help improve the man-
agement of systems to reduce risks and improve patient  safety. 
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 Adverse Drug Events ADEs (actual harm from medicines) are medication incidents 
defi ned as ‘any undesirable experience that has happened to the patient while taking a 
drug but which may or may not be related to the drug’ (MHRA, 2006). 
 Adverse drug events may be divided into two categories. 
  A  preventable ADE is an injury that is the result of an error at any stage through-
out the medication process. 
  A  non-preventable ADE is an injury due to a medication where there is no error 
in the medication process. Th ese are also referred to as  Adverse Drug Reactions 
(ADRs) . Th e MHRA defi ne ADRs as ‘an unwanted or harmful reaction experi-
enced, following the administration of a drug or a combination of medications, 
and is suspected to be related to the medication. Th e reaction may be a known side 
eff ect of the medication or it may be new and previously  unrecognized’. 
 Th e NPSA collects data on  all types of medication error and the MHRA collects 
data on adverse drug reactions via the Yellow Card System. Th erefore, it is impor-
tant that information is shared and data are processed between each of these 
 organizations. 
 Medication errors within the medication process 
 Th e medication process is the term used to describe the process of delivering medica-
tions to patients. It consists of fi ve stages. 
 Stage 1: Prescribing the medicine. 
 Stage 2: Dispensing the medicine. 
 Stage 3: Preparing the medicine for administration. 
 Stage 4: Administering the dose using the appropriate route and method. 
 Stage 5: Monitoring the eff ect of the medicine on the patient (NPSA,  2007 ). 
 Th e potential for error lies within each stage. 
 Stage1: Prescribing errors 
 Prescribing medicines is now no longer the sole responsibility of medical staff . A number 
of nurses, pharmacists  and optometrists have undertaken education to enable them to 
independently prescribe almost all the medications in the  British National Formulary, 
  
 Figure 10.1.  Demonstrates the correlation 
between medication errors, potential adverse 
drug events and preventable adverse drug 
events and non preventable adverse drug 
 reactions (Morimoto  et al .,  2004 ) 
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within their scope of clinical practice. Similarly, a number of allied health professions 
 (physiotherapists, radiologists, chiropodists/podiatrists) and optometrists , nurses and 
pharmacists may prescribe as supplementary prescribers, in partnership with a medical 
practitioner. 
 A prescribing error may be defi ned as the incorrect drug selection for a patient or 
errors involving wrong drug, dose, quantity, indication for use or a contraindication 
(Williams,  2007 ). Prescribing errors also include illegible handwriting, misspelling of a 
drug with a similar name and use of abbreviations. 
 Prescription errors are estimated as being between <1%  and 11% of all written pre-
scriptions (Sanders & Esmail,  2003 ). 
 Stage 2: Dispensing errors 
 Dispensing is carried out in a variety of settings from hospital pharmacies, community 
pharmacies and some rural General Practices. One common dispensing error is selec-
tion of the wrong product, usually where there are two drugs with similar proprietary 
names (e.g. Losec® and Lasix®), which may look similar when hand written. Other dis-
pensing errors include wrong dose, wrong drug and wrong patient and some reports 
suggest typing errors in computerized labelling as a common cause of error in dispens-
ing (Williams,  2007 ). 
 Stage 3 and 4: Administration and preparation errors 
 Th ere is very little documented data around preparation and administration errors 
occurring in patients in the community. However, there is a reported wide variation 
in the rates of preparation and administration error within hospitals with rates vary-
ing between 3.5% and 49% (NPSA,  2007 ). Th e NPSA also suggest that this wide range 
refl ects the diff erences in the defi nitions used to record medication error, together with 
methods of data collection. 
 Drug administration and preparation has been considered as an area of ‘high risk’ 
within nursing practice and the well-known six  Rights of the Medication Use Process 
should be familiar to all: 
 Right patient • 
 Right drug • 
 Right dose • 
 Right route • 
 Right time • 
 Right  outcome • 
 Many drug administration errors are errors of omission but also include failure 
to check patient identity, incorrect administration technique and administration of a 
wrong or expired drug (Williams,  2007 ). 
 Th e  literature suggests that the medication error rate for administration of intrave-
nous (IV) drugs may be as high as 25% and these errors have signifi cant risk to patients 
(Bruce & Wong,  2001 ). 
 One of the most common types of error identifi ed is ‘deliberate violation of guide-
lines’, for example, where practitioners have injected IV medication faster than the rec-
ommended time stated in the guidelines (Williams,  2007 ). 
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 Stage 5: Errors in monitoring outcome 
 With an increasing elderly population, there is a subsequent rise in patients living with 
long-term, oft en complex chronic diseases. Th is gives rise to issues of medicines man-
agement and the need for careful monitoring of outcomes. Some patients take certain 
drugs, which require continuous monitoring to ensure they are taking the optimum 
dose for their condition at the time. Literature suggests that recommended ongoing 
monitoring of patients taking certain drugs is not being undertaken by healthcare pro-
fessionals. Th e NPSA ( 2007 ) cite one study where less than one-third of patients taking 
diuretics were having the electrolyte levels in their blood monitored. Th is statement 
may be borne out by evidence stating diuretics as one of the medicines most common-
ly responsible for medicine-related admission to hospital (Pirmohamed  et al .,  2004 ; 
Howard  et al .,  2007 ). 
 Th e  Nursing and Midwifery Council (NMC) have produced Standards for  Medicines 
Management (2007), which sets standards for safe practice for supplying, administering 
and dispensing medicines to patients. 
 Th ere are also Standards of profi ciency for nurse and midwife prescribers (2006) and 
both these documents are available via the following link:   http://www.nmc-uk.org/ . 
 The extent of the problem 
 Th e Department of Health estimate that the annual cost of avoidable hospital admis-
sions resulting from drug errors cost in the region of £200-400 million per annum. 
 Pirmohamed  et al . ( 2004 ) carried out the largest UK study of hospital admissions 
data over 6 months and their fi ndings concluded that 6.5% of all admissions were 
related to harm from medicines. From these fi ndings the researchers concluded that 
4.7% of all admissions were as a result of avoidable harm from medicines. Th e medi-
cines most commonly responsible were aspirin, diuretics, warfarin and non-steroidal 
anti-infl ammatory drugs. More recently, a systematic review of international litera-
ture by Howard  et al . ( 2007 ) cited the drugs most commonly responsible for medi-
cine-related admission were antiplatelets, diuretics, non-steroidal anti-infl ammatory 
drugs and anticoagulants, which supports the UK  fi gures. 
 The  National Patient Safety Agency and The National 
Reporting and Learning System 
 England and Wales 
 Th e  National Patient Safety Agency (NPSA) was set up in 2001 and one of its main 
functions was to develop the National Reporting and Learning System (NRLS), which 
primarily collects information on reported patient safety incidents from local risk 
management systems in England and Wales. Th e NRLS dataset is designed to collect 
reports from any single patient safety incident immediately aft er it occurs. From the 
data collected, themes and patterns in the types of incidents being reported may be 
identifi ed including major systems failures, allowing development, promotion and 
implementation of solutions (WHO,  2005 ). 
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 Th e data are confi dential and no information is held on identities of individual staff  
or patients and the focus is on: 
 characteristics of the patient • 
  age 
  sex 
  ethnicity 
 patient outcomes • 
 any contributory factors • 
 factors which may have prevented harm. • 
 Th ere is also an area for free text for detailed explanations if  needed. 
 Brief summary of fi ndings from the NRLS data 
 Th e NPSA report Safety in Doses: medication safety incidents in the NHS (2007), was 
based on reports to the NRLS over a period of eighteen months, between January 2005 
and June 2006. Within the time period, 59 802 medication incidents were reported to 
the NRLS and included ‘near miss’ incidents.  Table 10.1 shows the ten most common 
types of reported patient safety incident. Th e fi gures demonstrate that medication inci-
dents are the second most frequent type of incident reported aft er patient accidents. 
 Settings 
 From the NPSA report ( 2007), it would appear that there is substantial under-reporting 
by NHS organizations, particularly within primary care settings. Although most pre-
scribing and dispensing is carried out in the community, over 80% of the medication 
incidents reported to the NRLS came from hospital reports with only 4.9% of medica-
tion incidents being reported from the primary care setting. 
 Non-NHS organizations such as those run by the local authority or the voluntary 
sector are not connected to the NRLS at  present. 
 Table 10.1.  The ten most common types of patient safety incident (NPSA,  2007 ) 
 Type of patient safety incident  Number  Percentage 
 Patient accident  278 886  38.8 
 Medication  59 802  8.3 
 Treatment, procedure  58 921  8.2 
 Access, admission, transfer, discharge (including missing patient)  55 710  7.8 
 Infrastructure (including staffi  ng, facilities, environment)  46 122  6.4 
 Documentation (including records, identifi cation)  35 533  4.9 
 Documentation (including records, identifi cation)  34 944  4.9 
 Clinical assessment (including diagnosis, scans, tests, assessments)  31 644  4.4 
 Consent, communication, confi dentiality  28 723  4.0 
 Medical device/equipment  23 389  3.3 
 Total  653 674  91.0 
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 Age groups 
 Although the patient’s age was indicated in less than half of all the reports to NRLS 
during the 18- month period, it would appear from the data that children between the 
ages of 0-4 years together with older adults peaking at 75–79 years are more likely to be 
involved in medication incidents. 
 Incidence occurrence during stages of the medication process 
 Almost 60% of reported incidences in hospital settings occurred during administra-
tion and supply. In the community, 62.9% of incidents occurred during preparation or 
dispensing. 
 One-third of trusts (mainly primary care trusts) reported no medication inci-
dents occurring over 6 months. More information would have been useful to  support 
these fi ndings as it is unclear as to whether one-third of trusts have had absolutely 
no medication incidents to report or whether there is a fundamental failure in their 
local reporting  systems. 
 Types of medication error 
 Two main types of error were found in over half of the reported incidents: wrong dose 
omitted medicines and wrong medicines. Th ese types accounted for almost 50% of the 
reported errors. Others included wrong quantity, mismatch between patient and medi-
cine, wrong/transposed/omitted medicine label, patient allergy to treatment, wrong 
storage and wrong/omitted/passed expiry date. 
 Outcome of error to patients 
 Outcomes of error were reported (Piramohamed,  et al .,  2004 ) by degree of harm to 
patients ranging from ‘no harm’, ‘low, moderate or severe harm’ to ‘death’. From the data, 
it appeared that more medication incidents resulted in ‘no harm’ than all other incidents 
reported to the NRLS. 
 Also, there were less medication incidents resulting in ‘death’ than all other patient 
safety incidents reported. Although the proportion of reported harm is small, there 
is no room for complacency. Remember that these fi ndings may also refl ect under 
 reporting. 
 Scotland 
 Following a baseline study carried out in 2005, ‘A Scottish prescription – managing the 
use of medicines in hospitals’, there were key recommendations made to NHS Quality 
Improvement Scotland (NHS QIS). One of these recommendations was ‘to develop a 
national approach to collecting data on adverse incidents, including medication inci-
dents, to allow robust trend analysis, transferable lessons and benchmarking’. 
 Between 2005 and 2007, QIS led an initiative to develop a standardized approach to 
incident and near-miss reporting across NHS Scotland. 
 Th e Scottish Government established the Scottish Patient Safety Alliance in 2007 
to guide the Scottish Patient Safety Programme and promote a systematic approach 
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to improving the safety of patients in hospital. It brings together the NHS, the Scottish 
Government, professional bodies and patient representatives in a new drive to signifi -
cantly reduce adverse events and improve patient safety (Audit Scotland,  2008). 
 Reporting patient safety incidents 
 What to report 
 Patient safety incidents to be reported are defi ned by the NPSA as ‘any unintended or 
unexpected incident which could have or did lead to harm for one or more patients 
receiving NHS care’. Th e NRLS was developed by the NPSA to foster a culture of open 
reporting, in order to learn from adverse events. 
 Th e reports are anonymous, although it may be that the trust or Health Board 
may be identifi able. Names of patients and staff  are removed prior to the information 
being stored in the database. Williams ( 2007 ) suggests there are signifi cant increases 
in the reporting of medication errors where confi dential ‘no-fault’ reporting has been 
implemented. 
 When to report 
 Th e NPSA encourages reporting of  all patient safety incidents and include the following 
in their criteria: 
 incidents you have been involved in; • 
 incidents you have witnessed; • 
 incidents which caused no harm (or minimal harm); • 
 incidents resulting in moderate or severe harm (including death); • 
 prevented patient safety incidents (near misses). • 
 Th e NPSA does not have the statutory power to make incident reporting mandatory. 
Th ere have been suggestions that reporting ought to be mandatory in a bid to combat 
under-reporting, yet the literature examining the causal factors for under-reporting 
does not appear to support this idea in principle. In 1976, Dr Bill Inman highlighted 
‘seven deadly sins’, which may account for low reporting rates. Th ese sins, as summa-
rized by Belton  et al . ( 1995 ), ranged from ‘ignorance’ (uncertainty of how to report), 
‘diffi  dence’ (looking foolish), ‘fear’ (of exposure to legal liability), ‘lethargy’ (too busy), 
‘guilt’ (reluctant to admit cause of harm), ‘ambition’ (preference to publish fi ndings) to 
‘complacency’ (only safe drugs are marketed). 
 Conversely, an attitudinal survey of Dutch physicians (Elland  et al .,  1999 ) reported 
the following fi ndings: 
 only 26% knew which ADRs to report; 
 93% thought the reaction was too well known to warrant reporting; 
 75% thought the reaction was trivial; 
 72% were uncertain whether the reaction was caused by a drug; 
 33% did not have enough time; 
 36% thought reporting was too bureaucratic; 
 22% did not know how to report; 
 18% were not aware of the need to report. 
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 From the Dutch fi ndings, it could be argued that mandatory reporting may improve 
under-reporting, although it would appear that emphasis on the importance of report-
ing and education on pharmacovigilance is essential. 
 Who reports? 
 Any healthcare staff  member may report a patient safety incident. Patients and carers 
may also report using a diff erent form. 
 Participation in the reporting mechanism is voluntary. 
 How to report 
 Most trusts and health boards have an electronic risk management system, which has a 
link enabling reports to be submitted directly into the NRLS. Establishments which do 
not have a direct electronic link may use the electronic reporting form or ‘eForm’ which 
has been developed by the NPSA. 
 Individual healthcare workers may report either via their local risk management 
system or directly via the NPSA website. 
 Th e eForm may be accessed via the following link  https://www.eforms.npsa.nhs.uk/
staff eform/ . 
 Patients and carers may also report safety incidents via the following link: 
https:// www.eforms.npsa.nhs.uk/eformPP/step1.do . 
 What happens to the report? 
 Th e information provided in each report is fed into the NPSA database. Considerable 
learning can be gained from the data as this provides information on ‘trends and pat-
terns in patient safety’ which enables solutions to be developed. 
 Lessons learned are disseminated through the publication of feedback such as: 
 NRLS Quarterly Data Reports; • 
 Patient Safety Alerts. • 
 Incident reports are not generally made available to the public, although some trusts 
and health boards may provide information to the public if deemed  necessary. 
 Reporting adverse drug reactions (ADRs) 
 A recent study by Pirmohamed  et al . ( 2004 ), determined that ADRs were related 
to 6.5% of adult hospital admissions and that in 80% of those, the ADR was the 
direct cause of admission. The study also found that ADRs accounted for 4% of all 
hospital admissions resulting in a projected annual cost to the NHS of £466 million. 
Further findings showed that the mortality rate of patients admitted with ADRs was 
 over 2%. 
 Reporting of ADRs began in 1964 following the thalidomide tragedy. In 1958, Dis-
taval® was advertised as being an ‘outstandingly safe’ medication which was ‘relatively 
free from side-eff ects’. It was commonly given to women during the fi rst 3 months of 
pregnancy to combat nausea and sleeplessness. Following a huge rise in the number of 
babies being born with deformities, Distaval® was withdrawn from sale in the UK from 
1961. 
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 As a direct result of the world-wide extent of the thalidomide tragedy, the Com-
mittee on Safety of Drugs was established in the UK in 1964 and was the world’s fi rst 
reporting mechanism for adverse drug  reactions. In 1971, the Committee on Safety of 
Drugs became the Committee on Safety of Medicine (CSM) and in 2005, the commit-
tee became the Commission on Human Medicines (CHM). It is an expert commit-
tee within the  Medicines and Healthcare Products Regulatory Agency (MHRA) whose 
duties include: 
 advising Ministers on matters relating to human medicinal products; • 
 advising the Licensing Authority (LA), including giving advice in relation to the • 
safety, quality and effi  cacy of human medicinal products; 
 considering representations made in relation to the Commission’s advice by an • 
applicant or by a licence or marketing authorisation holder; 
 promoting the collection and investigation of information relating to adverse • 
reactions for human medicines (except for those products that fall within the 
remit of ABRH or HMAC) for the purposes of enabling such advice to be given 
(MHRA,  2008). 
 How  to report adverse drug reactions 
 The  Yellow Card scheme 
 Th e Yellow Card scheme is a British initiative run by the MHRA and the CHM and it is 
used to gather information from anybody, health professionals and the general public, 
on suspected side eff ects or ADRs from: 
 prescription medicines; • 
 herbal remedies; • 
 over-the-counter medicines; • 
 ADRs suspected to be caused by unlicensed medicines in cosmetic treatments. • 
 Th e MHRA and its predecessor organizations have collected reports of suspected 
adverse drug reactions through the Yellow Card scheme for over 40 years. Since the 
establishment of the scheme, over 500 000 UK reports have been collected. Th e Yellow 
Card scheme acts as an early warning system for the identifi cation of previously unrec-
ognised reactions and enables identifi cation of risk factors, outcomes of the ADR and 
other factors that may aff ect clinical management. 
 Th e continued success of the scheme is dependent on the vigilance of UK healthcare 
professionals and their willingness to report suspect ADRs. Every report can make a 
diff erence. 
 The MHRA and CHM also have five Yellow Card Centres whose role focuses 
on follow-up of reports in their areas as this has been shown to improve follow-up 
rates. 
 Liverpool • 
 Cardiff  • 
 Edinburgh • 
 Newcastle-upon-Tyne • 
 Birmingham. • 
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 Access to Yellow Cards 
 Paper copies of Yellow Cards may be found in copies of the  British National Formulary 
(BNF), the  Nurse Prescribers’ Formulary (NPF), the  British National Formulary for Chil-
dren (BNFC), the  Monthly Index of Medical Specialties (MIMS) Companion and from 
the Association of the British Pharmaceutical Industry (ABPI)  Compendium of Data 
Sheets and  Summaries of Product Characteristics. 
 Electronic Yellow Cards may be accessed via the MHRA website  www.yellowcard.
gov.uk . 
 Who can report via the Yellow Card scheme? 
 All healthcare professionals and members of the general public may submit reports. It 
should be noted that patient reporting is undertaken using a diff erent form within the 
MHRA web site. 
 What should be reported via the Yellow Card scheme? 
 Any suspected ADR should be reported through the Yellow Card scheme. If there is any 
doubt around whether a patient has indeed suff ered from an ADR, it is good practice 
to report this anyway. It is important to remember that the cause does not need to be 
established beforehand. 
 It is essential to report all reactions for the following: 
 black triangle drugs; • 
 reactions in children; • 
 all serious reactions from established drugs and vaccines including those that are: • 
 fatal  ·
 life-threatening  ·
 disabling or incapacitating  ·
 result in prolonged hospitalization;  ·
 cause congenital abnormality;  ·
 medically signifi cant.  ·
 Areas of particular importance including:  ·
 delayed drug eff ect;  –
 elderly patients;  –
 ADRs associated with herbal remedies;  –
 congenital anomalies.  –
 Th e MHRA produced the fl owchart below to clarify when to report an ADR 
 Black triangle drugs 
 Black triangle products are new drugs and vaccines, which are being monitored more 
intensively in order to confi rm the risk/benefi t profi le of the product. Th ey are indi-
cated in reference texts by the inverted black triangle symbol (insert black triangle 
symbol here). 
 Healthcare professionals are encouraged to report  all suspected ADRs for black tri-
angle drugs, regardless of the seriousness of the suspected reaction. Black triangle prod-
ucts are usually new drugs but black triangle status can also be applied to: 
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 a new combination of active substances (even though those substances have been • 
previously licensed); 
 administration via a new route of administration or drug delivery system/device; • 
 A signifi cant new indication, which may alter the established risk/benefi t profi le • 
of the product. 
 Th ere is no standard time for a product to retain black triangle status. However, 
an assessment is usually made following 2 years of post-marketing experience and the 
black triangle symbol is not removed until the safety of the drug is well established 
(MHRA,  2008 ). 
 A list of black triangle products is available on the MHRA website:   www.mhra.gov.uk . 
 Serious reactions of particular importance 
 All serious reactions should be reported via the Yellow Card scheme; however, there 
are some areas of particular importance to the MHRA and these include children, the 
elderly, delayed drug eff ects, congenital anomalies and ADRs associated with herbal 
medicines. 
 Reactions in children 
 It is important to remember that many medicines routinely used for children are not 
licensed for use in this age group. All suspected ADRs that occur in children under 18 
years of age should be reported, regardless of whether the medicine is licensed for chil-
dren or not. Monitoring of drug safety is essential for this age group as children are not 
generally exposed to medicines within clinical drug  trials. 
 Reactions in elderly patients 
 Th e number of people over 65 years of age continues to grow. A high proportion of these 
patients receive medicines on a regular basis. Th e physiological changes that occur natu-
rally with ageing have an impact on pharmacokinetics and pharmacodynamics related 
to drug therapy in these patients. Th e elderly are more susceptible to the therapeutic and 
adverse eff ects of drugs. Elderly patients oft en receive multiple numbers of medicines for 
their multiple disease states, which increases the risk of drug side eff ects and drug interac-
tions. It is therefore important to monitor the safety of medicines in this age group. 
 Th e National Service Framework for Older People (2001) describes how to maxi-
mize the benefi ts of medicines and how to avoid excessive, inappropriate or inadequate 
consumption of medicines by older  people. 
 Delayed drug eﬀ ects 
 Delayed eff ects may be more diffi  cult to monitor as they may not manifest until months 
or years aft er exposure to a particular drug. Th e MHRA request that any suspicion of 
such an association is reported. 
 Congenital anomalies 
 If a baby is born with an abnormality, or if a pregnancy results in a malformed abort-
ed fetus, any suspicion of an adverse drug reaction during the pregnancy must be 
reported. 
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 Herbal medicines 
 There is a history of herbal products being perceived as ‘safe’ as they are thought 
of as being natural products. From a safety point of view, it is worth considering 
these products in the same way as conventional medicines for the following 
reasons. 
 Oft en they have not undergone adequate clinical trial testing. • 
 Th ey may not have a product licence. • 
 Th ey can cause unexpected adverse reactions and interact with other medicines – • 
there is oft en little documented evidence with regard to adverse reactions and 
interactions (Barnes  et al .,  2003 ). 
 What other information is needed? 
 Th ere are four crucial pieces of information needed when reporting an ADR: 
 • Suspected drug/drugs 
 Name of drug  ·
 Route of administration  ·
 Daily dose  ·
 Dates of administration  ·
 • Suspected reaction 
 Suspected drug reaction (including diagnosis if appropriate)  ·
 Date of reaction  ·
 Seriousness of reaction  ·
 Any treatment given for the reaction  ·
 • Patient details 
 Sex of patient  ·
 Age at time of reaction  ·
 Patient’s weight(if known)  ·
 Patient’s initials and local identifi cation number  ·
 • Reporter details 
 Full name and address  ·
 Any other information which may be relevant to the case should be  reported. 
 Improving reporting of medication incidents 
 NPSA seven priority areas for action 
 Th e NPSA ( 2007) have challenged the NHS organizations in their report, ‘Safety in 
doses: medication safety incidents in the NHS’, over some of their fi ndings highlighting 
weaknesses in current medication practice. 
 In order to improve patient safety, they have recommended seven priority actions 
for all staff  to implement and have determined priorities for both individual healthcare 
professionals and for NHS organizations. 
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 Increase reporting and learning from medication incidents 
 Recommendations to individual healthcare professionals. 
 Report any medication incidents either directly to NRLS via the website or  ·
through the local risk management system. 
 Ensure reporting medication incidents are included as an objective in  ·
personal development plans (PDPs). 
 Use refl ection and analysis of incidents to enhance your objectives for your PDP.  ·
 Recommendations for NHS organizations. 
 Ensure commitment at strategic level to improving patient safety.  ·
 Increase reporting of medication safety incidents.  ·
 Ensure quality assurance processes are in place by engaging the senior  ·
pharmacists with chief executive, medical and nursing directors to ensure 
incident reports are completed and reviewed. 
 Form a multidisciplinary group to carry out reviews of medication  ·
incidents, audit and initiate action to minimize risk. 
 Ensure regular feedback is given to all healthcare workers.  ·
 Produce a widely available annual report that summarizes incident reports  ·
and the learning gained from  them. 
 Implement NPSA safe medication practice recommendations 
 Since 2001, the NPSA has produced guidance in safe medication practice, particularly 
to help minimize the risks associated with the ‘high-risk’ medication practices. Th ese 
may be found on the NPSA website under Patient Safety Alerts  http://www.npsa.nhs.
uk/patientsafety/alerts-and-directives/alerts/. 
 Recommendations for individual healthcare professionals. 
 Read and implement the guidance produced by NPSA to help minimize  ·
risk in practice from these high-risk medications/medication practices. 
 Recommendations for NHS organizations. 
 Monitor and audit the NPSA guidance and evaluate improvements  ·
following inclusion of the information. 
 Share results of evaluations with Healthcare Commission and NHS  ·
litigation  organizations. 
 Improve staff  skills and competencies 
 Th e NPSA has developed multidisciplinary work-based competences as part of recent 
patient safety alerts such as anticoagulant therapy, the use of injectable medicines and 
paediatric infusions. Th ese e-learning competences are designed to help healthcare pro-
fessionals to acquire essential knowledge to allow them to practise safely. 
 Recommendations for individual healthcare professionals and NHS organizations. 
 Use the e-learning packages to help develop competence in the safe use of medicines.  ·
 Identify other competences which may be improved in the future by education and  ·
 training. 
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 Minimize dosing errors 
 From the NPSA report (2007) it would appear that dosing errors are the most frequently 
reported medication incident, with older adult and children being more commonly 
involved. 
 Recommendations for individual healthcare professionals. 
 Make full use of all accessible, essential information (national and local  ·
medicines information services and therapeutic protocols) when prescrib-
ing, dispensing, preparing, administrating or monitoring medicines. 
  · Always undertake the required safety checks on dosages. 
 If drug calculations are necessary, always have another member of staff   ·
calculate the dose independently from you. 
 Ensure all clinical monitoring and dosage adjustments are in place as and  ·
when required. 
 During prescribing, dispensing or administering medicines, ensure  ·
awareness of previous doses and any changes to patient’s condition that 
may result in an alteration to the dose of medicine. 
 Recommendations for NHS organizations. 
 Dosing errors must be audited and analysed to identify common local risks.  ·
 Ensure all appropriate staff  have access to essential information to enable  ·
them to prescribe, dispense, prepare, administer and monitor safely. 
 Review local and national policies to ensure they provide accurate guid- ·
ance to minimize risk. 
 Ensure staff  have access to (where available) calculation charts, soft ware,  ·
syringe drivers and ready-to-use products to avoid complex dose  calculations. 
 Ensure medicines are not omitted 
 Th e second largest cause of reported medication incidents, according to the NPSA 
report ( 2007 ) is omitted medicines. Th e report highlighted serious and fatal outcomes 
for omissions of certain drugs such as anticonvulsants and insulin. 
 Recommendations for healthcare professionals. 
 Do not ignore omissions caused by prescribing, dispensing or administer- ·
ing errors and report all serious omissions as a medication incident. 
 Recommendations for NHS organizations. 
 Evaluate and audit all reports of omissions and delays. Results should be  ·
used to target areas of high reporting and to ensure systems are appropriate 
to reduce likelihood for the future. 
 Review medicine storage and supply chains  regularly.  ·
 Ensure the correct medicines are given to the correct patient 
 Th is section deals with two ‘human error’ categories: 
 mis-selection of a drug 
 mis-identifi cation of a patient.  ·
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 Th e NPSA is working with the pharmaceutical industry to improve medication 
package design and labelling to avoid confusion and mis-selection of drugs, which may 
occur at any time in the medication process. 
 Recommendations for healthcare professionals. 
 Ensure awareness of drug names that look and sound alike. Colleagues should  ·
be alerted upon discovery of a drug that has a similar name to another. 
 Store medicines that look or sound alike in diff erent locations.  ·
 Use labels that alert other users to the risk.  ·
 Double check with a colleague before administration.  ·
 Liaise with pharmacy department to use medicines with safer designs to  ·
minimize risk. 
 For patients in hospital, avoid mis-identifi cation of these patients by  ·
checking identifi cation – using auto-ID technology (if available), hospital 
number, NHS number, date of birth and address where necessary. 
 Recommendations for NHS organizations. 
 Be aware of the risks of medications that look and sound alike. Improve the  ·
medication system. 
 Review reports of wrong medicine and wrong patient selection and  ·
identify medications most frequently mis-selected. Findings should be 
used to improve systems and minimize risk to patients. 
 Improve and develop purchasing for safety policies and medicines.  ·
 Ensure policies are in place for separate storage, alert labels and double  ·
checking to help minimize risk. 
 Consider auto-ID  technology.  ·
 Document patient’s medicine allergy status 
 As a signifi cant number of reported serious incidents involved patients who had a 
known allergy to medication, the NPSA have made the following recommendations. 
 Recommendations for healthcare professionals. 
 Ensure medication allergy status is documented in patient’s notes.  ·
 Do not prescribe, dispense or administer a drug if you are unsure of the  ·
patient’s allergy status. 
 Recommendations for NHS organizations. 
 Audit the frequency of medication incidents involving patient allergy.  ·
 Ensure all electronic prescribing and dispensing systems utilize a record of  ·
the patient’s allergy status so that an alert is given prior to prescription or 
dispensing. 
 For patients in hospital, use coloured wristbands for alerting staff  to  ·
patients with known medication allergy. 
 Ensure that systems are developed locally to ensure staff understand  ·
that some combinations of drugs may contain penicillin and could 
cause serious harm to patients with penicillin allergy (e.g. co-amoxiclav, 
 co-fluampicil). 
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 Th e NPSA also recommend that healthcare commissioners ensure that reporting 
and learning of medication incidents is a requirement for all commissioned services 
who are involved in the use of medicines. 
 All commissioned NHS organizations are also required to submit an Annual Report 
on their medication  practice. 
 NPSA and NHS confederation in March 2008 
 Five key changes to improve patient safety by strengthening reporting and learning 
 In March 2008, the NPSA, together with an NHS confederation, consisting of 20 of 
the organizations with the highest reporting fi gures, shared their experiences and 
produced a briefi ng outlining fi ve organizational changes to improve patient safety 
reporting. 
 Th e organization changes are briefl y summarized below: 
 Change 1: Give feedback to staff . 
 It was felt that feedback on reporting was encouraging for staff  and this motivated 
them to continue to report. 
 Methods of feedback included newsletters and case study reports among others. 
 Change 2: Focus on learning. 
 Th e focus of the ‘blame culture’ needs to shift  so that the focus is more about what 
has been learned from incidents so that improvements may be made in that particular 
area to improve patient safety. 
 Change 3: Engage frontline staff . 
 Th ere are suggestions about employing clinicians as ‘safety champions’ to fl ag up the 
issue at grass roots levels. 
 Change 4: Make it easy to report. 
 Access to forms needs to be easy with one well-designed form for all incidents. 
Organizations using web-based forms found improved consistency and effi  ciency in 
their reporting patterns. 
 Change 5: Make reporting matter. 
 It seemed that the organizations who robustly reported incidents had clear lines of 
strong leadership and their data were used to infl uence their decisions at a high  level. 
 Summary 
 In conclusion, it has been well documented that medication errors are seriously under-
reported and that the total number of reports have largely remained unchanged since 
the late 1980s. All healthcare professionals have a responsibility to report medication 
errors to help to reduce further recurrence. In order to improve reporting rates, there 
needs to be an increase in awareness of the need to report, together with standardized 
consistent education on the importance of pharmacovigilance as part of continuing 
professional development for all healthcare workers. 
 It is gratifying to see that, in recent years, the proportion of reports being submitted 
by nurses and pharmacists has increased (MHRA, 2008). With increased participation 
by other healthcare professionals in medications management and prescribing, perhaps 
it is now time for mandatory reporting of medication errors. 
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